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INTRODUCTION 
Liver transplantation is the only definite treatment modality for patients with 
end-stage liver cirrhosis. A major function of the predictive model is to 
accurately assess the probability of mortality within a given time interval, so 
that a timely liver transplantation can be performed.  
The Child score, which was first proposed in the 1960s and then modified as 
the Child-Turcotte-Pugh (CTP) score. The selection of predictors and 
construction of the CTP system were empirical, and the system contains 
parameters that were felt very important to affect the outcome. 
Although never formally validated as a prognostic tool, the CTP score is 
useful to assess the relative risk of mortality in patients with cirrhosis and 
has been popular for the past 3 decades. However, a major defect of the CTP 
system is a relatively narrow score range from 5 to 15. While the waiting list 
of liver transplantation is rapidly growing and patients on the waiting list far 
out number the cadaveric liver donors, the priority of patients with the same 
CTP score awaiting transplantation becomes difficult to judge.  
A simple first-come, first-served principle was proposed and used in the 
transplantation society [1]. However, investigators subsequently found that 
patients with a longer waiting time may actually have a less severe degree of 
cirrhosis. It was later demonstrated that waiting time is not a factor that 
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affects survival and was abandoned as a criterion in organ allocation. 
Another potential inherent flaw of the CTP system is that it contains 
subjective variables, including the severity of encephalopathy and ascites, 
which may be greatly influenced by personal judgment from center to center 
during status interpretation. These drawbacks compromise the fairness of 
organ allocation in liver transplantation.  
The concept of a model for end-stage liver disease (MELD), initiated by the 
Mayo Clinic group in 2000[2], emerged and was aimed to amend these 
defects.  The MELD was originally created for the prediction of mortality 
after Transjugular Intrahepatic Porto systemic Shunt [3]. On the basis of 
simple, readily available, and reproductive variables [serum creatinine, 
bilirubin, international normalized ratio (INR), and initially etiology], the 
MELD allows the identification of patients with end-stage liver disease and 
a median survival as short as 3 months.3 Because of the objective nature of 
its components and its ability to identify increasing death risk, this score was 
adopted by the United Network for Organ Sharing (UNOS) in place of the 
CTP score for the allocation of livers from deceased donors [4].  If the MELD 
represents determinant progress in terms of methodology and validation, its 
accuracy for the prediction of outcome in cirrhotic patients is also not 
always superior–and may even be inferior–to the one of CTP score[5][6]. 
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Hence, this study is to evaluate the superiority of CTP vs. MELD score in 
prediction of outcome in patients with End stage Liver disease, who are 
listed for liver transplantation. 
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AIM 
 
The main aim of this prospective study was to compare the accuracy of  
the Child-Pugh score and the  MELD  score for the prediction of 3 month 
and 6 month survival in cirrhotic patients waiting for liver transplantation.                               
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REVIEW OF LITERATURE 
Thomas Starzl carried out the first human liver transplant in 1963 in Denver. 
Initially the outcomes were very poor; however the persistence of Starzl and 
his team was rewarded and in 1968, Calne set up the second transplant 
program in Cambridge.   
Patients were usually very sick at the time of transplant and few survived 
the post-operative care. Over the next two decades, the numbers of patients 
grafted gradually increased and survival rates improved. There is no one 
reason for this improvement, but better selection, improved anaesthetic and 
surgical techniques, the use of powerful and specific anti-microbial and 
immunosuppressive agents all made significant contributions. In the 1980s, 
new programs developed primarily in North America and in Europe. Now 
liver transplantation has become a routine procedure for patients with end-
stage liver disease. 
The decision to consider liver transplantation is based on: 
1. An assessment of the severity of liver failure. 
2. The prognosis for the patient in response to current medical/surgical 
therapy 
3. The quality of the patient’s life (as a consequence of the liver disease) 
4. The judgment on the potential for liver transplantation to restore the 
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patient’s health. 
The determination of suitability is independent of the underlying diagnosis, 
and for that reason the conditions for which liver transplantation may be an 
appropriate therapy constitute a list of almost all liver diseases. 
The Donor Organ Shortage 
The source for donor livers in the western world is almost exclusively from 
heart beating brain dead donors. Sophisticated schemes are required to 
identify potential donors, retrieve their organs and transport the organs to the 
location of the potential recipient. At the same time, the number of potential 
recipients awaiting liver transplant continues to grow at a furious pace, 
outstripping the modest increases in donor numbers. This has meant that 
there are many more recipients for every donor liver. Thus in the United 
States in 2000, there were over 17000 patients on the waiting list, only 4579 
cadaveric transplants done and 371 living related transplants. There were 
1347 deaths on the waiting list [7]. The disparity between donor availability 
and recipient number has led to growing numbers of patients on the waiting 
list for liver transplant. 
Innovative responses to the donor shortage have been introduced but while 
these approaches may help relieve the situation, they are unlikely to ease the 
effects of the organ shortage. 
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1. Non-heart beating donors. Non-heart beating donors are uncommon, 
and the frequency of primary graft non-function and later, biliary strictures 
are greater in these allografts. 
2. Split livers—the division of a cadaveric organ between two recipients. 
However, only some cadaveric donor livers are suitable for splitting. 
3. Living donation—the harvesting of liver segments from living donors. 
Many recipients lack a family member or friend who is suitable or willing 
for living donation. Moreover, living segmental liver transplantation poses 
real risks of morbidity and even mortality (1% or more) for the donor. 
4. Use of marginal donors and extended use donor organs 
Marginal donors: some donor livers are associated with a higher 
probability of primary non-function (the so-called marginal donor). Marginal 
organs include those from older or obese donors, or donors who are unstable 
prior to organ retrieval. Other marginal grafts include steatotic livers, in 
which histology demonstrates greater than 25% microvesicular or 
macrovesicular fat. These grafts are associated with a higher incidence of 
primary non-function of the allograft. 
Extended use organs from patients infected with present or past viral 
hepatitis B or C and those with extrahepatic malignancy or treated bacterial 
infection. Organs from virus-infected donors are matched to a recipient 
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already infected by the same virus, albeit only after the recipient is apprised 
and has given consent. An example would be putting an anti-hepatitis C 
positive liver into an antihepatitis C positive recipient, or an anti-HBcore 
positive liver into an HBsAg positive recipient. 
5. Xenotransplants: the use of genetically modified animals, such as pigs or 
primates, is still a very long way from clinical use. While some of the 
problems of hyperacute rejection may be overcome, problems, such as 
chronic rejection, freedom from introducing infection (such as the porcine 
endogenous retrovirus (PERVs) as well as physiological concerns make it 
unlikely that this approach will provide a solution to the organ shortage 
in the next decade. 
6. Increasing organ donation: There are wide variations in the rates of 
organ donation—between 8 and 37 donors per million. Attempts to increase 
organ donation by education have largely failed: the most successful model 
in Spain is dependent on provision of a well-organized system of donor 
co-ordinators and acceptance cell transplantation and hepatocyte 
transplantation. Thus, it is unlikely that these methods will meet the needs of 
all potential recipients. 
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Selection for Liver Transplantation 
Evaluation of candidates for liver transplantation can be reduced to three 
core questions: 
• What is the severity and prognosis of the patient’s liver disease? 
• Are there confounding medical, surgical or psychological factors 
which would reduce the expectation of a liver transplantation? 
• What are the wishes of the patient in regards to liver transplantation? 
These questions are best addressed in a multidisciplinary process. The 
evaluation may be carried out in an outpatient setting.  
 
The prospective candidate is assessed by transplant surgeons and physicians, 
social workers, and selected subspecialists including psychiatrists, 
cardiologists, pulmonologists and nephrologists. Previous investigations 
including radiographs and biopsies are retrieved and new investigations are 
ordered where necessary. When the information gathering segment of the 
evaluation is complete, the patient is presented to the transplantation 
evaluation committee and a decision is made regarding placement on the 
transplant waiting list. 
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Liver transplant programs must inform and educate prospective recipients 
and their families of the risks and benefits of liver transplantation. It is 
important to provide the patient with the opportunity to withdraw from 
transplant assessment if they do not wish to proceed. Conversely, whenever 
the transplant program determines that the patient is not a suitable candidate; 
the program should facilitate the patient in receiving a second opinion 
regarding their suitability, if they should so wish. 
 
Indications for consideration of liver transplantation in patients with 
chronic liver disease 
Recurrent gastroesophageal variceal hemorrhage 
Refractory ascites 
Spontaneous bacterial peritonitis 
Severe hepatic encephalopathy 
Hepatorenal syndrome 
Hepatopulmonary syndrome 
Hepatocellular carcinoma 
Severe coagulopathy due to liver failure 
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Absolute contraindications 
Severe (uncontrolled) infection outside the hepatobiliary system 
Metastatic cancer (except some neuroendocrine cancers) 
Extra hepatic cancer (other than local skin cancer) 
Cholangiocarcinoma 
Advanced cardiopulmonary disease 
AIDS 
Severe pulmonary hypertension 
Technical considerations (e.g., widespread intra-abdominal venous 
thrombosis) 
Relative contraindications 
Recent drug or alcohol abuse 
Age >70 years 
HIV infection, without AIDS 
Inability to be compliant with immunosuppression protocol and/or 
participate in routine post-transplant medical follow-up 
Advanced chronic renal disease 
Moderate pulmonary hypertension. 
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Allocation and Distribution of Donor Livers 
Different countries have adopted different approaches to allocation of  
cadaveric donors of solid organs for transplantation: 
US: In the US, there is no Federal limitation on the number of transplant 
centers. Patients are centrally listed and available organs allocated to the 
individual recipient. At present allocation gives priority to the sickest 
patient. The greatest priority is given to patients with fulminant hepatic 
failure or primary allograft non-function, and for certain pediatric 
indications. For all other candidates, priority is determined by the MELD or 
PELD (the pediatric scoring system) score. An adjustment has been made 
for patients with hepatocellular cancer. 
UK: The number of centers designated for NHS (public funded) treatment is 
controlled by central government. The six transplant units have areas 
(according to their contracted activity) and any organ offered in their area 
can be used for a listed patient. Supra-urgent patients (those with fulminant 
hepatic failure) will have national priority. The individual unit determine 
which recipient should receive donor organs offered to that area. The units 
have agreed indications and contra-indications to ensure equity and justice. 
(See www.uktransplant.org.uk) 
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Europe: European countries have adopted a range of approaches to organ 
retrieval, allocation and distribution. 
Timing of Placement on the Waiting List 
A useful approach to the often difficult questions regarding timing of 
placement of a patient with liver disease on the transplant waiting list is to 
consider compensated (or stable) and decompensated cirrhosis.  
Stable Cirrhosis: is defined as cirrhosis in a patient who has never 
experienced any one of the four cardinal features of decompensation: 
variceal hemorrhage, accumulation of ascites, jaundice associated with 
cirrhosis, or encephalopathy. 
Decompensated cirrhosis: cirrhosis and the onset of at least one of these 
clinical phenomena is defined as decompensated cirrhosis. The onset of 
decompensation is associated with significantly impaired survival and 
indicates the need to evaluate for liver transplantation. Spontaneous bacterial 
peritonitis and or hepatorenal failure are indicators of significantly worsened 
prognosis, and should prompt transplantation evaluation. 
Indications for evaluation of liver transplantation are listed above. 
Paradoxically, some of these indications may, when severe, become 
contraindications to transplantation. 
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Assessment of Severity and Prognosis of Chronic Liver Disease 
The severity of liver failure in patients with chronic liver disease can be 
assessed by several models although the two models currently used are the 
Child-Pugh classification and the MELD score. 
Child-Turcotte-Pugh Class  
In the Child Pugh classification scoring is done based on the following 
parameters listed in the table.  
Child-Turcotte-Pugh classification 
Variable 1 2 3 
Encephalopathy 
 
None Grade I or II Grade III or IV 
Ascites 
 
None Mild  Moderate 
Bilirubin (mg/dl) 
 
<2 2-3 >3 
Albumin (g/dl) 
 
>3.5 2.8-3.5 <2.8 
Prothrombin time  
Prolongation in seconds 
INR 
 
 
<4 
 
<1.7 
 
 
4-6 
1.7-2.3 
 
>6 
>2.3 
Scores are summed to determine Child’s class: A=5-6, B = 7-9 & C=10-15. 
The initial version of Child or Child–Turcotte score [8], included two 
continuous variables (bilirubin and albumin) and three discrete (quantitative) 
 15
variables (ascites, encephalopathy and nutritional status). Again, the 
selection of these five variables as well as the cut-off values for bilirubin and 
albumin are empirical. The five variables and their respective cut-off values 
were arranged so as to define three distinct groups of increasing severity (A, 
B and C). Patients whose individual values fall into different groups could 
not be categorized. Therefore, variables have been ascribed 1, 2 and 3 points 
according to whether their values fell within the limits of groups A, B and C, 
respectively. The score is the sum of these points, ranging from 5 to 15. It is 
generally (but not universally) accepted that patients with a score between 5 
and 8 belong to group A, patients with a score between 9 and 11 belong to 
group B and patients with a score between 12 and 15 belong to group C. 
 A modified version, termed Child–Pugh score, has been proposed almost 10 
years later [9] , In this modified version, nutritional status is replaced by 
Prothrombin time. A difficulty comes from the fact that, across different 
countries, prothrombin has been expressed either as a time value 
(prothrombin time in seconds) or as a percentage of the activity of normal 
plasma (Prothrombin index or ratio). It can be estimated that the original cut-
off values of 4 and 6 seconds for prothrombin time correspond to a ratio of 
approximately 50% and 40% of normal, respectively. The lowest cut-off 
value for albumin has been changed from 30 to 28 g/l. The score, 
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corresponding to the sum of individual points, allows to categorize patients 
in Child– Pugh grades A (5–6 points), B (7–9 points) and C (10–15 points). 
Importantly, the total range of points (5–15) is not equally distributed across 
grades A, B and C, probably in an attempt to mirror more efficiently the 
clinical impact of the each grade in terms of prognosis. 
The variables included in Child–Pugh score are often considered as 
reflecting the synthetic (albumin and prothrombin) and elimination 
(bilirubin) functions of the liver. However, this concept may be viewed as an 
oversimplification. Indeed, albumin is influenced not only by hepatic 
synthetic function but also by transvascular escape or clearance, favoured by 
sepsis [10] and ascites [11]. Similarly, bilirubin is increased in case of renal 
insufficiency, hemolysis, and sepsis [12], all of which are not uncommon in 
patients with cirrhosis. Decreased prothrombin index may be related to the 
activation of coagulation, the major cause of which is sepsis [13]. Metabolic 
encephalopathy can be precipitated by sepsis or renal insufficiency [14]. As a 
result, albumin, bilirubin, prothrombin and encephalopathy represent 
prognostic markers coming from a broader source than the pure assessment 
of liver ‘functions’. Thus, Child–Pugh score may be viewed as a multiorgan 
assessment in patients with underlying cirrhosis rather than a simple 
estimate of liver functions. 
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Child score and subsequently, Child–Pugh score were initially proposed in 
the limited setting of the evaluation of surgery for portal hypertension 
(portacaval shunting and transection of the oesophagus) [9]. However, its 
prognostic value has been demonstrated in many other situations involving 
cirrhosis over the last 30 years. In particular, multivariate analyses using 
Child–Pugh score as an entity have shown that it has an independent 
prognostic value in the settings of ascites[15],ruptured oesophageal varices [16] 
subclinicalencephalopathy[17],hepatocellular carcinoma [18],liver surgery [19], 
alcoholic cirrhosis [20], decompensated HCV-related cirrhosis [21], primary 
sclerosing cholangitis [22], primary biliary cirrhosis [23] and Budd–Chiari 
syndrome [24]. Interestingly, the prognostic information provided by the 
addition of different markers of liver metabolism (such as the elimination of 
galactose, ICG, aminopyrine, or lidocaine) to the variables of Child–Pugh 
score is limited [25–28]. Similarly, the addition of usual anthropometric 
markers of nutritional status does not seem to add much to the predictive 
value of Child–Pugh score [29]. This finding is in contrast with the initial 
assumption made in Child– Turcotte score which, in contrast to Child–Pugh, 
included nutritional status [8]. 
The main application of Child–Pugh score has been to stratify or to select 
patients for prognostic analyses, for retrospective assessment of non-
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randomly administered therapy, or for randomized clinical trials. Contrasting 
with its wide validation as a prognostic index, Child–Pugh score is seldom 
incorporated into algorithms for the management of individual patients, with 
the exception of patient selection for surgical resection of hepatocellular 
carcinoma [30] or for extrahepatic surgery [31]. However, at the bedside, 
Child– Pugh score is widely used as a simple descriptive or prognostic 
indicator and is frequently associated to other indicators. 
A first limitation is related to the fact that the five basic components of 
Child–Pugh score have been selected empirically. It can be argued that 
studies reported thereafter, have shown that these variables do have a 
statistically significant impact on the outcome [32, 33–37]. However, not all 
variables have an independent influence. It can be anticipated, for instance, 
that albumin and coagulation factors, both synthesized by the liver, are 
strongly correlated to each other. Including these two variables in a single 
score might result in overweighting their influence. Only multivariate 
analysis allows selecting variables, which do not fully interfere with each 
other. 
 A second limitation comes from the arbitrary use of cut-off values for the 
quantitative variables. Neither there is evidence that these cut-off values are 
optimal for defining significant changes in mortality risk, nor there is 
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evidence that mortality risk increases linearly across Child’s grades A, B and 
C. For example, a patient with a bilirubin level of 3 mg/dl will be 
categorized in the same bilirubin class (class C) that a patient with a 
bilirubin level of 30 mg/dl. This represents a ‘ceiling effect’ on quantitative 
variables which does not exist with continuous scores derived from 
regression models. 
 
And further limitations are due to the fact that important prognostic factors 
are not taken into account. In particular, a number of studies have 
emphasized the determinant influence of renal function in the course of 
cirrhosis [15, 33, 35, 36]. For instance, the weight of creatinine is more than twice 
as high as that of bilirubin in MELD score [36]. 
Other studies have shown that markers of portal hypertension including 
oesophageal varices [38], portal blood velocity [39] and hepatic venous 
pressure gradient [26] provide additional prognostic information when added 
to the variables of Child–Pugh score. 
Lastly, Child–Pugh score does not take into account the cause of cirrhosis, 
the possible coexistence of several causal factors, and the persistence of a 
damaging process such as persistent alcohol abuse, ongoing HBV or HCV 
replication, or inflammatory activity of autoimmune hepatitis [34, 40]. 
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In previously reported studies, the variation in survival explained by Child–
Pugh score remains low (less than 50%), as it is the case with most survival 
models [41] emphasizing the fact that other factors play an important role in 
prognosis. 
 
MELD Score 
The complex issues of optimal indications for transplantation and 
prioritization for the allocation of liver grafts have been the main incentives 
to the development and widespread diffusion of MELD score. However, it 
must be noted that MELD score has been originally created with the aim of 
predicting survival after Transjugular intrahepatic portosystemic shunt 
(TIPS)[36], a context that may differ from that of candidates for 
transplantation. On the basis of multivariate analysis using Cox model, the 
authors found 
that, among a list of predetermined variables, four objective variables had a 
significant and independent impact on survival; namely bilirubin, creatinine, 
INR and the cause of cirrhosis (alcoholic and cholestatic versus other 
causes). 
Logarithmic transformation of quantitative values has been used in order to 
lessen the influence of extreme values in statistical analysis. A regression 
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coefficient has been attributed to each prognostic variable as a reflect of 
their proper weight on mortality. For a given patient, the final risk score (the 
ancestor of the current MELD score), derived from a survival function, is as 
follows: R=0.957 loge (creatinine [mg/dl]) + 0.378 loge (bilirubin [mg/dl]) + 
1.120 loge (INR) + 0.643 (cause of cirrhosis). ‘Cause of cirrhosis’ is quoted 
0 if alcoholic or cholestatic and 1 for all other causes. Unfortunately, this 
score does not allow a direct estimation of the probability of survival at a 
given time for one patient with given values of creatinine, bilirubin and INR. 
Estimating the probability of survival needs further computation based on 
the survival function of the model. A pocket chart that can be used for 
estimating life expectancy with individual values has been proposed. 
Unfortunately, the normogram is not really friendly for use at the bedside. In 
the same series, Child–Pugh score, although significantly correlated with a 
poor outcome on univariate analysis, could not accurately predict survival on 
multivariate analysis. Interestingly, Child–Pugh score was particularly 
inaccurate in the subgroup of patients of grade B with renal impairment, 
highlighting the key importance of renal function in cirrhosis. 
For years, the allocation of liver grafts had been based on waiting time. 
However, important studies clearly showed that waiting time is not an 
appropriate marker of the risk of death on the waiting list, warranting other 
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criteria for more efficient and fair organ placement [42]. Again, attention 
skipped from TIPS to transplantation. In a subsequent study [2], a slightly 
modified score, termed MELD, was tested in different populations of 
cirrhotic patients. For ease of use, the score was multiplied by 10 and 
rounded, giving the following formula: MELD score = 9.6 loge (creatinine 
mg/dl) +3.8 loge (bilirubin mg/dl) + 11.2 loge (INR) + 6.4 (cause of 
cirrhosis [0 if cholestatic or alcoholic, 1 otherwise]). This study showed that 
MELD score adequately predicts mortality in hospitalized as well as 
ambulatory cirrhotic patients, that the model is generalizable to patients with 
various causes and severity of cirrhosis, that MELD score is a useful scale 
for assessing On the grounds of these results, MELD score was finally 
adopted in the United States in 2002 as the reference scoring system to rank 
patients for liver transplantation. Practically, two additional modifications 
have been performed so far. Firstly, the variable referring to the cause of 
cirrhosis (cholestatic or alcoholic versus other causes) has been abandoned 
and replaced by a constant value. As a result the current score is as follows: 
9.6 loge (creatinine mg/dl) + 3.8 loge (bilirubin mg/dl) + 11.2 loge (INR)+ 
6.4.  
Secondly, candidates with HCC  are listed with a MELD score equivalent to 
a 10% (24 points) or 15% (29 points) risk of death within 3 months 
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according to which the tumor is classified as stage I or II. Stage I 
corresponds to a single nodule less than 2 cm. Stage II corresponds to a 
single nodule between 2 and 5 cm, or 2 or 3 nodules each less than 3 cm. By 
February 2003, these additional MELD points have been lessened to 20 and 
24, respectively, because it was felt that patients with HCC had over-
prioritization. Nonetheless, these patients if not transplanted within 3 
months, receive additional MELD points equivalent to a 10% increase in 
pre-transplant mortality every 3 months until they are transplanted or 
determined to be unsuitable for transplantation, because of excessive tumor 
progression. This latter change has been done because a significant 
proportion of patients with HCC have a compensated cirrhosis and low 
MELD score. Although they are good candidates for transplantation, they 
would be unlikely to be transplanted, unless receiving ‘extra’ points  
 
In contrast to Child–Pugh score, the variables of MELD score have been 
selected in a given population and the score has been validated thereafter in 
an independent sample [2, 36]. Recently, studies have been reported 
confirming that MELD is a robust risk score in patients undergoing TIPS, 
with c statistics for 1 year survival of about 0.70 [33,43]. Lastly, MELD score 
has been tested in the setting of acute liver failure and emergency 
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retransplantation for early graft failure. It has been suggested that MELD 
score is significantly correlated to mortality risk in patients with non-
paracetamol-induced acute liver failure while, in contrast, there is no 
correlation between MELD score and mortality in those with paracetamol 
overdose or early graft failure [44]. Nonetheless, the use of MELD score in 
patients with acute liver failure, whether related or not to paracetamol, seems 
highly questionable since neurological status, a crucial prognostic index in 
this context, is not taken into account. 
 
The application of MELD score for ranking candidates for transplantation 
gave the opportunity to assess prospectively its advantages over waiting time 
and UNOS status for prioritization in the US. By comparing data from two 
time periods, before and after MELD, a recent evaluation has shown that the 
application of MELD score for prioritization resulted in a 12% decrease in 
the total number of new candidates listed for transplantation [45]. Practically, 
less patients with low risk scores were listed to ‘take place’ on the list and 
take advantage of it in terms of waiting time. In addition, there was a 3.5% 
reduction in mortality on the waiting list (a difference which was not 
statistically significant as compared to pre-MELD period), a 10% increase in 
the total number of deceased donor transplantation (which is unlikely to 
 25
result solely from MELD score) and no significant change in post 
transplantation survival [45]. After additional points were ascribed to patients 
with small HCC, a significant decrease in the interval between listing and 
transplantation as well as a significant decrease in the rate of dropout from 
the waiting list due to tumor progression were observed [46]. However, a 
perverse effect of the system was that, in parallel, there was a threefold 
increase in the number of patients listed with a diagnosis of HCC. 
Importantly, there was also a significant increase in the proportion of 
patients who were found to have a misdiagnosis of HCC and no identifiable 
tumor on the explanted liver [47]. It is often difficult to ascertain the 
malignant nature of small nodules (<1 cm) within a cirrhotic liver, even with 
current imaging techniques [48]. The current allocation system obviously 
incites to categorize patients as having a small HCC, even when the 
malignancy is not clearly demonstrated. 
In contrast to its ability to evaluate pre-transplant mortality risk in  
candidates for transplantation, pre-transplantation MELD score seems to be 
a poor predictor of  post transplantation  survival, except for extreme values  
(>35) [49–51]. Indeed, post-transplantation survival depends on many factors 
other than recipient’s condition, most of which (in particular those related to 
the donor and technical issues) are unknown or elusive at the time of listing. 
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Limitations 
MELD score shares with Child–Pugh score several limitations. First, the use 
of multivariate analysis to determine which variables will be included in the 
final score can be viewed as more reliable than empirical selection of 
variables. However, multivariate analysis is performed on the basis of 
variables, which initially were also selected empirically because they were 
felt to have a potential prognostic influence. Therefore, it cannot be excluded 
that some important variables have not been taken into account for analysis. 
It is worth noting that some of the most widely accepted prognostic scores, 
such as TNM (for Tumor Node Metastasis), Glasgow coma scale and 
APACHE score rely on predictive variables selected empirically and not 
statistically. 
Second, variables included in MELD score, in contrast to encephalopathy 
and ascites, are theoretically objective and not influenced by subjective 
appreciation. However, in practice, creatinine and bilirubin can be altered by 
therapeutic interventions (diuretics in particular), sepsis or hemolysis. The 
choice of INR rather than other markers of coagulation including 
prothrombin time and Prothrombin index is a controversial issue. Another 
group found a very similar correlation [35] suggesting that INR can be 
reliably estimated from prothrombin ratio for retrospective purposes.  
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There are also some proper limitations to MELD score. While its principal 
application has been liver transplantation and allocation of donors, MELD 
score has been established among a population of candidates for TIPS. 
Although MELD proved to be a robust and efficient prognostic score in 
candidates for transplantation [6], it is possible that a score specifically 
tailored for liver transplantation could have been even more effective in this 
setting. 
Another limitation comes from the absence of clear-cut discriminant values 
with MELD score. With time, hepatologists have been used to deal with the 
simple limits of Child–Pugh’s class A, B and C. Such discriminant limits 
with MELD score have not yet been determined in a broad scope of 
situations. A prospective evaluation of MELD score in different situations 
(or for different therapeutic interventions) might lead to different cut-off 
values, rendering the decision process more complex than with the universal 
use of Child–Pugh classes. 
The principal limitation of MELD score is the need for computation, 
limiting its usefulness at the bedside. MELD, derived from a study focussing 
on TIPS patients, has not been anticipated to be widely used. Logarithmic 
transformation of quantitative variables has been chosen to improve 
significance and fit in the statistical model. However, there is no clear 
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evidence that statistical refinements translate in an identifiable improvement 
in accuracy and reproducibility. 
As an example, the cause of cirrhosis played a statistically significant and 
independent role in the original model. However, it seems that the accuracy 
did not change much when the cause of cirrhosis was eventually removed 
from the list of variables [2, 36]. Whether a simplified score using the same 
objective variables, but without the need for computation would give a 
similar accuracy is worth being tested. 
 
 
 
 
 
 29
MATERIALS AND METHODS 
 
It was a prospective study between January 2008 and Dec 2009, where 
consecutive patients with cirrhosis attending the liver clinic of Government 
Stanley Medical College & Hospital were studied.  
Inclusion criteria: Patients with an initial CTP score of 7 or more (equivalent 
to class B or C) to fulfill the minimal listing criteria for liver transplantation, 
were included.  
 
The diagnosis of liver cirrhosis was based on the characteristic findings 
including physical stigmata of cirrhosis, decreased serum albumin, and 
increased serum globulin levels, computed tomography or ultrasonography 
findings of uneven liver surface, coarsened echogenicity of liver 
parenchyma, enlarged spleen and/or detection of ascites, and detection of 
esophageal varices by endoscopy. The presence and severity of ascites were 
detected and evaluated by computed tomography or ultrasonography. The 
definition of hepatic encephalopathy was according to the West Haven 
criteria. 
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The underlying etiology of liver disease was attributed to hepatitis B virus 
(HBV) infection if patients were seropositive for hepatitis B surface antigen 
(HBsAg, RIA kits, Abbott Laboratories, North Chicago, IL) and attributed 
to hepatitis C virus (HCV) infection if patients were seropositive for 
antibody against HCV by a second-generation enzyme immunoassay 
(Abbott Laboratories, IL) on at least two occasions.  
 
The CTP scoring system is classified from A to C and calculated on the 
basis of serum bilirubin and albumin levels, the prothrombin time (PT), and 
the presence and severity of ascites and encephalopathy.9 To obtain the 
MELD score for the patients, the Internet accessed at: www.unos.org or: 
www.mayo.edu/int-med/gi/model/mayomodl-5-unos.htm. 
 
The study was approved by the institutional review board and all patients 
who participated in the study gave a written informed consent. 
 
Statistical Analysis 
Chi-squared test or Fisher’s exact test (two-tailed) was used for categorical 
data. Spearman’s correlation analysis was used to estimate the correlation 
between MELD and CTP system. To assess the ability of MELD and CTP 
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score in predicting the risk of death, this study was performed by measuring 
the concordance (c-statistic) equivalent to the area under the receiver 
operating characteristic (ROC) curve. Receiving-operating-characteristic 
(ROC) curve and the derived c statistic provide a global and standardized 
appreciation of the accuracy of a marker or a composite score for predicting 
an event. This statistic allows a simple comparison of the accuracy of 
different prognostic scores within the same population. ROC curve 
represents the plotting of sensitivity against 1-specificity. A c statistic of 0.5 
means that discrimination is due to chance alone. A c statistic of 1 means 
that the score perfectly predicts outcome (a goal never achieved in clinical 
practice). Therefore, the accuracy of a score increases when c statistic moves 
from 0.5 to 1.  Comparison of the area under ROC curves was done using 
the method of Hanley and McNeil. The outcome was assessed as 3-month 
and 6-month mortality. All statistical analyses were conducted using SPSS 
for Windows version 12 (SPSS, Inc., Chicago, IL) and MedCalc for 
Windows version 4.2 (MedCalc Software, Mariakerke, Belgium). For all 
tests, a P value less than 0.05 was considered statistically significant. 
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                                          RESULTS 
A total of two hundred and one patients were enrolled during the study 
period. Among them, 5 patients who underwent liver transplantation during 
the follow-up were excluded from analysis. The natural history and outcome 
were assessed for the remaining 196 cirrhotic patients who formed the basis 
of this study.  
Clinical characteristics and demographic data of patients included in the 
study are shown in Table 1.The mean age of patients was 45.9 years (range 
18 to 65 years). 
 Of the 196 patients, 150 were male and 46 were female. Patient who 
underwent transplantation during the observation period were excluded for 
this analysis. Forty patients died during the study period and 5 patients were 
successfully transplanted. The mean CTP score was 7.44 (range 7 to 12) and 
mean MELD score of all patients was 10.35 (range 6 to 41).  
Of the 196 study patients, 16 (8.16%) and 40 (20.4%) patients died at 3- and 
6-month respectively.  
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Table 1. Patient Characteristics and variables at the time of listing among 
Survivors and Non-survivors on waiting list. 
 Total no of pts On waiting list Died on waiting list 
Patients  196      156 40 
Age (years) 45.9 45.8 46.1 
Male /Female 150/46 113/43 37/3 
Etiology of liver disease 
Cirrhosis-alcoholic 82 66 16 
Cirrhosis- HBV 33 29 4 
Cirrhosis- HCV 13 11 2 
Others 78 60 18 
Complications 
Bleed 121 99 22 
HE 38 17 21 
HRS 26 10 16 
SBP 8 5 3 
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Of the 196 patients 41.8%of patients suffered from alcoholic liver disease 
and 23.4% from virus hepatitis-induced cirrhosis. Other etiologies accounted 
for 39.7%. 
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The Variceal Bleed represents a major complication constituting 61.7% and 
Hepatic Encephalopathy was noted in 19.3% of the study population     
The presence of Hepatorenal syndrome (HRS) and Spontaneous Bacterial 
peritonitis (SBP) as complications of Liver cirrhosis were noted in 13.2% 
and 4% of patients respectively.  
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Table 2 : Follow up CTP scores are listed below 
  
 
  
Group 
Student independent 
t-test 
Waiting list Died on list 
Mean SD Mean SD 
CTP0 7.40 .49 7.63 .77 t=1.72 p=0.09 
CTP3 7.39 .49 8.90 1.39 t=6.75 p=0.001 
CTP6 7.88 1.19 9.48 1.41 t=5.15 p=0.001 
 
CTP0   = CTP score done at baseline. 
CTP3 = CTP score done at 3rd  month. 
CTP6 = CTP score done at 6th  month. 
 
 
The Mean CTP score at baseline, 3 months and 6 months was 7.4, 7.39 and 
7.88 respectively for patients in the waiting list and 7.63, 8.9 and 9.48 
respectively for patients who died on waiting. 
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Table 3: Follow up MELD  scores are listed below  
 
 
 
Group 
Student independent t-
test 
On Waiting list Died on list 
Mean SD Mean SD 
MELD0 10.35 1.77 10.80 3.35 t=0.81 p=0.41 
MELD3 10.37 1.74 17.25 7.61 t=5.68 p=0.001 
MELD6 12.99 5.33 20.57 5.81 t=5.98 p=0.001 
 
MELD0   = MELD score done at baseline. 
MELD3 = MELD score done at 3rd  month. 
MELD6 = MELD score done at 6th  month. 
 
 
The Mean MELD score at baseline, 3 months and 6 months was 10.35, 
10.37 and 12.99 respectively for patients in the waiting list and 10.8, 17.25 
and 20.57 respectively for patients who died on waiting. 
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The ROC curve for CTP score at 3 months is 0.73 at CTP score  7.5 and also 
at 6 months at CTP value of 8.5 the C-STAT is 0.73 . 
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Table 4: Coordinates of the Curve for CTP score 
 
 
 
 
 
 
 
 
 
 
 
 
 
Test results Variable(s) 
 
Positive if 
Greater Than 
or Equal To(a) Sensitivity 1 - Specificity 
c0 6.00 1.000 1.000 
7.50 .478 .404 
8.50 .087 .000 
10.00 .000 .000 
c3 6.00 1.000 1.000 
  7.50 .739 .391 
8.50 .391 .000 
9.50 .043 .000 
11.00 .000 .000 
c6 6.00 1.000 1.000 
  7.50 .913 .513 
8.50 .739 .205 
9.50 .522 .083 
10.50 .217 .051 
11.50 .087 .032 
13.00 .000 .000 
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Graph 2 
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The ROC curve for MELD score at 3 months is 0.73 at MELD score 10.5 
and also at 6 months  MELD score  value of 15.5 the C-STAT is 0.82 . 
 
 
 
 
 41
Table 5: Coordinates of the Curve   for MELD score 
Test Result Variable(s) 
Positive if 
Greater Than or 
Equal To(a) Sensitivity 1 - Specificity 
m0 5.00 1.000 1.000 
  6.50 .957 1.000 
  7.50 .826 .962 
  8.50 .652 .769 
  9.50 .522 .641 
  10.50 .304 .583 
  11.50 .130 .301 
  12.50 .043 .077 
  13.50 .043 .019 
  15.00 .043 .000 
  17.00 .000 .000 
m3 6.00 1.000 1.000 
  7.50 1.000 .968 
  8.50 .957 .750 
  9.50 .826 .673 
  10.50 .739 .615 
  11.50 .696 .282 
  12.50 .565 .071 
  13.50 .522 .013 
  14.50 .435 .000 
  15.50 .348 .000 
  16.50 .261 .000 
  17.50 .130 .000 
  18.50 .087 .000 
  20.00 .000 .000 
m6 5.00 1.000 1.000 
  6.50 1.000 .962 
  7.50 1.000 .910 
  8.50 1.000 .853 
  9.50 .957 .756 
  10.50 .957 .615 
  11.50 .913 .500 
  12.50 .913 .410 
  13.50 .913 .340 
  14.50 .870 .269 
  15.50 .826 .218 
  16.50 .826 .212 
  17.50 .783 .205 
  18.50 .783 .179 
  19.50 .696 .122 
  20.50 .435 .103 
  21.50 .348 .071 
  22.50 .261 .058 
  23.50 .174 .032 
  24.50 .174 .026 
  26.00 .130 .026 
  28.00 .043 .013 
  33.50 .043 .006 
  39.50 .000 .006 
  42.00 .000 .000 
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Comparison of the Area under Curve (AUC) at 3- and 6-Month between 
MELD and CTP Score.  
The area under ROC of the CTP and MELD score at 3 months (0.73 vs. 
0.73) and at 6 months (0.73 vs.  0.82).  
A cut off point of 8.5 CTP score has been found optimal to predict 
sensitivity of 73.9% and specificity of 79.5%.  
A cut off point of 15.5 for the MELD score has been found optimal to 
predict Sensitivity of 82.6% and specificity of 78%. 
However, when the performance of the two scores was compared at 3 and 6 
months, no statistical significant difference could be found between them. 
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Comparative Analysis of CTP and MELD scores between the Survivors and 
Non survivors. 
 
MELD score
50454035302520151050
C
TP
 s
co
re
13
12
11
10
9
8
7
6
group
Died
Alive
 
When CTP score more than 10 and MELD score more than 15 increase the 
risk of survival for patients on waiting list. These patients have benefit from 
Liver transplantation. 
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DISCUSSION 
 
Child Pugh score is the commonly used prognostic model to predict the 
survival in cirrhotic patients and for organ allocation. The disadvantage of 
using child score is due to inclusion of subjective parameters and variation 
in the lab values. Whereas in MELD score, the parameters used are of the 
objective type and better in identifying increasing death risk. The results of 
various studies and present study which compares the CTP and MELD score 
in predicting survival are described below. (Table 6). 
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Table 6. Predictive value of CTP and MELD Score for Survival in Patients 
with Chronic Liver Disease. 
Reference Year Study 
population 
Patients  End point C stat  
CTP 
C stat 
MELD 
Angermayr et al  2002 Chronic liver 
disease 
475 3 month 0.70 0.72 
Botta F et al 
 
2003 Cirrhosis 1291 1 year 
mortality  
0.69 0.67 
Wiesner RH et al.  
 
2003 Cirrhosis 3437 3 month 
mortality  
0.76 0.83 
Giannini et al 2004 Chronic liver 
disease 
145 3 months 0.75 0.95 
Daniel Gotthardt 
et al 
2009 Cirrhosis 268 2 years 0.73 0.68 
Present study 2009 Cirrhosis 196 6 month 
mortality  
0.73 0.82 
 
Angermayr et al.,[33] analysed retrospectively the largest series (n = 475) of 
cirrhotics who had elective TIPS placement. In multivariate analysis, MELD 
was the single independent predictor for both overall and 3-month survival. 
However, the predictive accuracy of MELD score for 1-month, 3-month and 
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1-year survival was not significantly different, compared with the CTP (c-
statistics for 3-month survival: 0.72 vs. 0.70). 
Botta et al [6]. evaluated the short- and medium-term prognosis in a 
European series of 129 cirrhotics followed for at least 1 year, comparing the 
MELD and CTP scores. All patients had monoethylglycinexylidide (MEGX) 
test. They recorded 12 deaths within 6 months and 31 within 1 year of 
follow-up. MELD score showed significant correlation with both MEGX (r 
= 0.542, P < 0.0001) and CTP (r = 0.817, P < 0.0001). The c-statistics for 
CTP, MELD and MEGX were similar for 6-month (0.82, 0.79 and 0.82, 
respectively) and 12-month survival (0.69, 0.67 and 0.68, respectively). 
Wiesner RH et al [52] ,in their prospective study, MELD score was applied to 
estimate 3-month mortality to 3437 adult liver transplant candidates with 
chronic liver disease  between November 1999 and December 2001. In this 
study cohort with chronic liver disease, 412 (12%) died during the 3-month 
follow-up period. Waiting list mortality increased directly in proportion to 
the listing MELD score. Patients having a MELD score <9 experienced a 
1.9% mortality, whereas patients having a MELD score ≥40 had a mortality 
rate of 71.3%. Using the c-statistic with 3-month mortality as the end point, 
the area under the receiver operating characteristic (ROC) curve for the 
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MELD score was 0.83 compared with 0.76 for the Child-Turcotte-Pugh 
(CTP) score (P < 0.001).  
Giannini et al [53] evaluated the predictive values of MELD and CTP scores 
for 3-month mortality in 145 European cirrhotic patients. Comparison of the 
c-statistics for CTP and MELD scores, showed that the MELD score was 
significantly better than the CTP score (0.95 vs. 0.75) . 
Daniel Gotthardt et al [54] in 2009 studied 268 consecutive patients listed for 
single-organ liver transplantation for non fulminant liver disease between 
2003 and 2005. Comparing the predictive abilities of CTP and MELD 
scores, the best discrimination between patients still alive on the waiting list 
and patients who died on or were removed from the waiting list was 
achieved at a CTP score of ≥9 and a MELD score of ≥14.4. The sensitivity 
and specificity to identify mortality or severe deterioration for CTP was 
69.0% and 70.5%, respectively and for MELD, it was 62.1% and 72.7% 
respectively. This result was supported by the AUC analysis showing a 
strong trend for superiority of CTP over MELD scores (AUROC 0.73 and 
0.68, resp.; p = 0.091). 
Botta F et al., and Daniel Gotthardt et al compared CTP and MELD shows 
CTP is good in predicting survival over MELD score in contrast to the  
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study by  Angermayr et al, Wiesner RH et al, and  Giannini et shows MELD 
score is good in predicting survival over CTP score .  
In the Present study, CTP and MELD scores had almost identical 
discriminative ability for 3 month (0.73 vs. 0.73) survival, but MELD score 
was better in predicting 6 month( 0.82 vs. 0.73) survival compared with CTP  
score. In this Present study MELD score is good in predicting survival over 
CTP score which is supported by the above studies.  
Analyzing the data, it is evident that MELD is superior to the CTP scoring 
system in predicting the survival in patients waiting for Liver 
transplantation. 
Possibly, the most important study limitations were the relatively small 
sample size and the major drawbacks of the MELD score related to wide 
variability of laboratory parameters such as serum creatinine and bilirubin. 
The clinical scenario of patients with early to late stage cirrhosis may vary 
widely, appropriate modifications and fine tuning of MELD are necessary in 
determining the ranking status of patients on the waiting list, in order to 
avoid futile transplantations. 
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SUMMARY 
 
The study was done in 201 patients with end stage liver disease who were 
waiting for liver transplantation. Five patients underwent Liver 
transplantation during observational period and were excluded from the 
study. The remaining 196 patients were taken in to the study. This was 
undertaken to assess the predictor of survival at 3 month and 6 month period 
on waiting list.  
A detailed history elicited as per proforma enclosed and through 
examination done. The baseline investigation which includes Hemogram, 
blood sugar, Serum Creatinine, Liver function test and Prothrombin Time 
(INR) were done .The Baseline, 3 month and 6 month CTP and MELD 
scores were calculated. The mean age of the study population was 45.9 years 
(18-65). Of the 196 patients, 150 were male and 46 were female. 41.8%of 
patients suffered from alcoholic liver disease and 23.4% from virus 
hepatitis-induced cirrhosis.  
Other etiologies accounted for 39.7%. The Mean CTP score at baseline, 3 
months and 6 months was 7.4, 7.39 and 7.88 respectively for patients in the 
waiting list and 7.63, 8.9 and 9.48 respectively for patients who died on 
waiting. 
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The Mean MELD score at baseline, 3 months and 6 months was 10.35, 
10.37 and 12.99 respectively for patients in the waiting list and 10.8, 17.25 
and 20.57 respectively for patients who died on waiting. 
This study shows CTP and MELD scores had almost identical discriminative 
ability for 3 month (0.73 vs. 0.73) survival, but MELD score was better in 
predicting 6 month( 0.82 vs. 0.73) survival compared with CTP  score.  
Thus, there is good evidence to support the fact that MELD is superior to the 
CTP scoring system in predicting the survival in patients waiting for Liver 
transplantation. 
Child-Pugh classification has been a reference for more than 30 years for 
assessing the prognosis of cirrhosis. MELD score comes as the most serious 
challenger for replacing Child-Pugh score and overcoming its limitations. 
The principal advantages of MELD score are that  
1. Variables selected based on statistical analysis rather than clinical 
judgment. 
2. Variables are objective and unlikely to be influenced by external 
factors. 
3. Each variable is weighted according its proper influence on prognosis.  
In listed patients for liver transplantation, the CTP score more than 10 and 
MELD score more than 15 increases the risk of mortality. These patients are 
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prioritized in the list for Liver transplantation to achieve maximum benefit 
of transplantation. However to overcome the pitfalls of MELD scoring 
system, modification can be done to include other clinical and biochemical 
parameters for predicting better survival. 
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CONCLUSION 
 
The present study highlights the following, 
• The prognostication based on Child Pugh and MELD scores had 
almost identical discriminative ability for predicting 3Month (0.73 vs. 
0.73) survival in patients on Transplant Waiting list.  
• The MELD score was better in predicting 6 month (0.82 vs. 0.73) 
survival when compared with CTP score. 
• A cut off point of 8.5 CTP score has been found optimal to predict 
sensitivity of 73.9% and specificity of 79.5%. 
• A cut off point of 15.5 for the MELD score has been found optimal to 
predict Sensitivity of 82.6% and specificity of 78%. 
In the setting of Liver transplant, the MELD may score better over the CTP 
score in determination of priorities for organ allocation. 
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SNO Name Age Sex MGE No Alcohol HBV HCV
1 paneerselvam 52 1 3638/09 1 2 2
2 sekar 50 1 4752/09 1 2 2
3 deivannai 60 2 486/08 1 2 1
4 papammal 57 2 912/09 1 2 2
5 samydurai 45 1 5883/07 2 1 2
6 shankari 35 2 47285 2 2 2
7 raja 39 1 4712/09 1 2 2
8 kannagi 29 2 1034/05 1 1 2
9 selvi 40 2 5335/09 2 1 1
10 ponmarimuthu 40 1 2267/09 1 2 2
11 ALAMELU 50 2 5103/09 1 2 2
12 sathyanathan 55 1 6379/09 1 2 2
13 ranganathan 58 1 4302/09 2 2 2
14 Gandhi 55 1 1752/09 1 2 2
15 armugam 39 1 1927/08 2 2 2
16 durairaj 53 1 5394/03 1 2 2
17 sukumar 51 1 3118/09 1 2 2
18 dominic savio 49 1 4202/02 1 2 2
19 Rajasekar 48 1 6210/09 1 2 1
20 kamali 30 2 1532/06 2 2 2
21 shantakumar 52 1 4955/07 2 2 2
22 Balaji 18 1 4441/04 2 2 2
23 shankari 27 2 1136/07 2 2 2
24 duraiappan 36 1 1584 1 2 2
25 Uma 24 2 1514/04 2 2 2
26 subramani 38 1 2192/06 1 2 2
27 chengalvarayan 50 1 6185/08 2 2 2
28 baskar 46 1 3155/09 2 2 2
29 Dhanasekaran 47 1 3063/09 2 2 2
30 selvaraj 42 1 4506/02 2 2 2
31 Kesavan 40 1 1385/09 1 2 2
32 srinivasan 35 1 6280/07 2 2 2
33 mohammed ali 43 1 6464/09 2 2 2
34 vasudevan 45 1 796/08 1 2 2
35 sivaprasad 46 1 4215/08 2 2 2
36 almas 48 2 1166/01 2 2 2
37 sahasranamam 44 2 4817/09 1 2 2
38 kotti 55 1 4784/09 1 2 2
39 Rani 50 2 6048/09 1 2 2
40 raman 47 1 7065/07 2 1 2
41 vijayaraghavan 50 1 4839/08 2 2 2
42 vasu 40 1 2507/09 1 2 2
43 Parthasarathy 47 1 6355/09 2 2 2
44 lakshmi 40 2 1618/08 2 2 2
45 sekar 30 1 6557/07 2 2 2
46 kuppamal 40 2 1726/05 2 2 2
47 Krishnan 58 1 476/06 1 2 2
48 VELLAPONDI 44 1 4984/09 2 2 2
49 Jayalakshmi 50 2 5458/09 2 2 2
50 Kurshith begam 48 2 736/04 2 2 2
51 hariprasad 5 1 3954/09 2 2 2
52 raja 50 1 2760/09 2 2 2
53 ethiraj 51 1 5550/09 2 1 2
54 gunasekahar 58 1 4770/08 1 2 2
55 prakasam 52 1 3726/05 1 1 2
56 theboral 40 2 2973/06 2 2 2
57 Mohan 48 1 3988/07 1 2 2
58 vasantha 30 2 630/06 2 2 1
59 murali 40 1 1468/06 2 1 2
60 ekambaram 48 1 4339/09 1 2 2
61 vimal 23 1 1723/09 2 1 2
62 Loganayaki 39 2 1022/05 2 1 1
63 gajapathiraja 32 1 3540/09 2 1 2
64 murthy 36 1 4904/07 2 1 2
65 Subramani 63 1 4906/07 1 2 2
66 Kandasamy 64 1 5737/09 2 2 2
67 selavaraj 63 1 4623/09 2 2 2
68 thangavelu 65 1 459/06 2 2 2
69 Kothandan 55 1 6360/04 2 1 2
70 Banu 21 2 3765/09 2 2 2
71 SELVAM 45 1 5189/09 1 2 2
72 loganathan 45 1 3942/09 1 2 2
73 george 57 1 5196/09 2 1 1
74 RAJA 36 1 5435/09 1 1 2
75 Samsang mahariba 63 2 5683/09 2 2 1
76 gangadharan 57 1 6665/07 1 2 2
77 Kasim 36 1 5594/09 1 2 2
78 Pushparaj 46 1 899/09 2 1 2
79 Gunasekaran 49 1 6642/09 1 2 2
80 Ramesh 40 1 5392/09 1 2 2
81 Moorthi 47 1 4242/09 1 2 2
82 Chandra 40 2 6282/09 2 2 2
83 Umar Basha 50 1 1813/08 1 2 2
84 Azeezunisha 58 2 5170/09 2 2 2
85 Nagammal 58 2 5944/09 2 2 2
86 shanmuganathan 51 1 4774/09 2 1 2
87 Ravi 48 1 28/08 1 2 2
88 krishnan 50 1 4815/09 2 1 2
89 baskar 57 1 54/09 1 2 2
90 kuppan 48 1 4500/09 1 2 2
91 Rathinam 55 1 4196/09 2 2 2
92 viswanathan 33 1 4614/08 1 2 2
93 Rajendran 57 1 54/09 1 2 2
94 panchpeer 46 1 6538/04 2 2 2
95 selvakumar 30 1 5450/9 1 2 2
96 mohanraj 40 1 2867/07 2 2 2
97 kannan 36 1 2798/09 2 2 2
98 subbulakshmi 25 2 4788/09 2 2 2
99 Bhavani 31 2 1011/08 2 2 2
100 MUNIAMMAL 37 2 5000/09 2 2 2
101 rajasundar 40 1 1398/09 2 1 2
102 suresh babu 53 1 4688/04 2 2 2
103 kothandan 23 1 1490/05 2 2 2
104 maragathammal 45 2 3464/08 2 2 2
105 Narayanan 48 1 1421/06 2 1 2
106 kasturi 46 2 1285/01 2 2 2
107 suresh kumar 20 1 5901/09 2 2 2
108 JANARTHANAN 35 1 5605/09 2 2 2
109 Janarathanan 35 1 3367/09 2 2 2
110 Kumar 49 1 5889/09 1 2 2
111 satheswaran 55 1 5965/07 1 2 2
112 varadharajan 56 1 280/06 1 2 2
113 gopal 54 1 4584/05 2 2 2
114 Santhanam 18 1 6041/09 2 2 2
115 Iqbal 48 1 6415/09 2 2 2
116 Parvathy 38 2 3768/06 2 2 2
117 lakshmi 50 2 4566/07 2 2 2
118 Krithika 30 2 6015/08 2 2 2
119 rani 40 2 7208/07 2 2 2
120 kasturi 52 2 6744/03 2 1 2
121 lakshmi 55 2 6321/07 2 1 2
122 punniyakodi 55 1 1401/09 1 2 1
123 manohar 44 1 3312/09 1 2 2
124 chandrasekar 53 1 2980/07 2 2 2
125 shanmugam 41 1 3652/09 1 2 2
126 subramanin 54 1 4479/09 1 2 2
127 sudhakar 45 1 4941/09 1 1 2
128 kondiah 70 1 2584/06 2 2 2
129 ramados 53 1 6528/09 1 2 2
130 marthamma 65 2 4114/09 2 2 2
131 Babu 60 1 6320/08 1 2 2
132 Ganesan 65 1 6392/07 2 2 1
133 kathija bee 65 2 2647/09 2 2 1
134 Mohan 48 1 4613/09 1 2 2
135 annathai 64 1 4869/03 1 2 2
136 Unnamalai 58 2 2590/01 2 2 2
137 kadiravan 43 1 2015 1 2 2
138 gandhi 40 1 5628/09 1 2 2
139 VIJAYA 35 2 202 2 2 2
140 vasuki 40 2 3417/04 2 2 2
141 sarfuddhin 49 1 6572/09 1 2 2
142 DHARANIKARASI 42 2 932 2 1 2
143 Royappan 42 1 1433 1 2 2
144 vijaya kumar 38 1 1451 1 2 2
145 babu 35 1 378 1 1 2
146 siva 45 1 546/09 1 2 2
147 ganesan 55 1 1276/09 2 1 2
148 ramaraj 60 1 3700/08 2 1 2
149 Ramesh 35 1 6241/09 1 2 2
150 chinnasamy 48 1 3935/09 1 1 2
151 kannaiyan 64 1 653/09 1 2 2
152 Sankarammal 50 2 1965/05 2 1 1
153 appandai raj 65 1 1769/08 2 2 2
154 Mahalingam 64 1 75/09 1 2 2
155 Razia 42 2 3285/08 2 2 2
156 mani 55 1 2514/09 2 1 2
157 elangovan 58 1 4566/09 2 1 2
158 Kuppusamy 65 1 2453/09 2 2 2
159 Subramani 50 1 4108/07 1 2 2
160 Chandrasekar 51 1 5344/09 2 2 2
161 selvaraj 55 1 4362/09 2 1 2
162 ravi 44 1 3354/09 1 2 2
163 pedhuru 29 1 5753/09 1 2 2
164 Dr.dhansekar 51 1 5999/09 2 2 1
165 K. Krishnamoorthy 59 1 6349/09 2 2 2
166 sekar 56 1 13983 1 2 2
167 Chandrasekar 18 1 801/07 1 2 2
168 Kuppusamy 44 1 19306 2 1 2
169 Kumar 38 1 21334 1 2 2
170 Santhanu Kishore 60 1 29494 1 2 2
171 Kanniyakumar 21 1 1517/08 2 2 2
172 Leelavathy 63 2 38171 2 2 2
173 Balaji 50 1 39018 2 2 2
174 Harish Doshi 52 1 40181 1 2 2
175 Basha 45 1 43127 1 2 2
176 varlaxmi 40 2 1014/05 2 2 2
177 stanley 54 1 4036/06 1 2 2
178 sivasakthi 45 1 38321 1 2 2
179 selvaraj 41 1 33245 1 2 2
180 Pannerselvam 18 1 36176 2 2 2
181 prabu 23 1 34158 2 2 2
182 Md Safi 48 1 42167 2 2 2
183 Devaraj 59 1 23145 1 2 2
184 ravikumar 40 1 6966/07 2 2 2
185 Tamilmani 50 1 2105/07 2 2 2
186 Jeelani syed 49 1 3224/04 2 2 2
187 Ellapan 49 1 650/07 2 2 2
188 Prasad 57 1 5971/08 2 2 2
189 khaiser ahmed 36 1 4080/07 2 2 2
190 Satyanarayanan 28 1 4888/07 2 2 2
191 ashok joshi 45 1 4118/08 1 2 2
192 pandian 42 1 3996/08 1 2 2
193 kumarapillai 56 1 1558/04 2 2 2
194 Rajeswari 50 2 215/08 2 2 1
195 Prasanna Kumar 45 1 5092/09 1 2 2
196 Thirunavukarasu 63 1 512/08 2 1 2

others Variceal BleH E HRS SBP bilirubine a Creatinine INR at baseAlbumin at 
2 1 1 1 2 1.1 1 1.2 2.9
2 1 1 2 2 1.1 1 1.3 2.8
2 2 2 2 2 1.2 1.2 1.1 2.2
2 2 2 2 2 1 0.8 1.2 2.4
2 1 1 1 2 1.2 0.7 1.4 2.1
1 2 2 2 2 2.1 1.1 1.3 2.2
2 1 2 2 2 1.2 0.7 1.2 2.6
2 2 2 2 2 1.1 0.9 1.4 2.1
2 1 2 2 2 2.3 1.1 1.4 1.9
2 1 2 2 2 1.1 0.6 1.2 2.1
2 2 2 2 2 0.7 0.8 1.2 2.1
2 1 2 2 2 1.2 0.8 1.3 2.2
1 2 2 2 2 1.1 0.9 1.1 1.9
2 1 2 2 2 1.2 1.1 1.2 2.1
1 2 2 2 2 2.1 1.2 1.1 1.9
2 1 2 2 2 1.3 0.8 1.2 2.1
2 1 2 2 2 0.8 0.7 1.1 2.4
2 1 2 2 2 1.4 1.1 1.3 1.8
2 1 2 2 2 1.2 0.7 1.1 2.3
1 2 2 2 2 2.3 0.7 1.2 2.1
1 1 2 2 2 2.1 1.1 1.2 2.6
1 2 2 2 2 1.4 1.2 1.4 2.8
1 2 2 2 2 0.8 0.9 1.2 2.4
2 1 2 2 2 0.7 1.2 1.4 2.1
1 2 2 2 2 1.1 1.2 1.2 2.4
2 1 2 2 2 3.1 1 1 2.1
1 2 2 2 2 2.1 1.1 1.1 2.4
1 1 2 2 2 1.1 0.8 1.1 2.2
1 2 2 2 2 1.4 0.6 1.3 2.6
1 2 2 2 2 0.8 0.6 1.5 2
2 1 1 1 1 0.6 0.8 1.2 2.4
1 1 2 2 2 1.4 0.7 1.1 2.8
1 2 2 2 2 1.3 0.8 1.4 2.6
2 1 2 2 2 1.1 1.1 1.3 2.9
1 2 2 2 2 1.6 1.2 1.2 2.2
1 2 1 2 2 0.9 1.2 1.1 2.3
2 1 1 1 2 2.1 1.1 1.2 2.6
2 1 2 2 2 2.1 1.1 1.3 2.2
2 1 1 2 1 1.2 0.7 1.2 2.6
2 1 2 2 2 1.1 0.9 1.4 2.1
1 1 2 2 2 2.3 1.1 1.4 1.9
2 1 2 2 2 1.1 0.6 1.2 2.1
1 2 2 2 2 0.7 0.8 1.2 2.1
1 2 2 2 2 1.2 0.8 1.3 2.2
1 2 2 2 2 1.1 0.9 1.1 1.9
1 1 2 2 2 1.2 1.1 1.2 2.1
2 2 2 2 2 2.1 1.2 1.1 1.9
1 1 2 2 2 1.3 0.8 1.2 2.1
1 1 2 2 2 0.8 0.7 1.1 2.4
1 1 2 2 1 1.4 1.1 1.3 1.8
1 2 2 2 2 1.2 0.7 1.1 2.3
1 2 2 2 2 2.3 0.7 1.2 2.1
2 1 2 2 2 2.1 1.1 1.2 2.6
2 1 2 2 2 1.4 1.2 1.4 2.8
2 1 2 2 2 0.8 0.9 1.2 2.4
1 2 1 2 2 0.7 1.2 1.4 2.1
2 2 2 2 2 1.1 1.2 1.2 2.4
2 1 2 2 2 3.1 1 1 2.1
2 2 2 2 2 2.1 1.1 1.1 2.4
2 1 2 2 2 1.1 0.8 1.1 2.2
2 1 2 2 2 1.4 0.6 1.3 2.6
2 1 2 2 2 0.8 0.6 1.5 2
2 1 2 2 2 1.3 0.8 1.2 2.1
2 2 2 2 2 0.8 0.7 1.1 2.4
2 1 2 2 2 1.4 1.1 1.3 1.8
1 2 2 2 2 1.2 0.7 1.1 2.3
1 2 1 1 1 2.3 0.7 1.2 2.1
1 2 2 2 2 2.1 1.1 1.2 2.6
2 1 2 2 2 2.1 1.1 1.3 2.2
1 2 2 2 2 1.2 0.7 1.2 2.6
2 2 1 1 2 3.1 1 1 2.1
2 2 2 2 2 2.1 1.1 1.1 2.4
2 2 2 2 2 1.1 0.8 1.1 2.2
2 2 2 2 2 1.4 0.6 1.3 2.6
2 1 2 2 2 0.8 0.6 1.5 2
2 1 2 2 2 0.7 1.2 1.4 2.1
2 1 2 2 2 1.1 1.2 1.2 2.4
2 2 2 2 2 3.1 1 1 2.1
2 1 2 2 2 2.1 1.1 1.1 2.4
2 1 2 2 2 1.1 0.8 1.1 2.2
2 1 2 2 2 1.4 0.6 1.3 2.6
1 2 2 2 2 0.8 0.6 1.5 2
2 1 2 2 2 0.6 0.8 1.2 2.4
1 1 2 2 2 1.3 0.8 1.4 2.6
1 1 2 2 2 1.4 0.7 1.1 2.8
2 1 2 2 2 1.1 0.9 1.1 1.9
2 1 2 2 2 1.2 1.1 1.2 2.1
2 1 2 2 2 2.1 1.2 1.1 1.9
2 1 1 2 2 1.3 0.8 1.2 2.1
2 1 2 2 2 0.8 0.7 1.1 2.4
1 1 2 2 2 1.4 1.1 1.3 1.8
2 1 1 2 2 1.2 0.7 1.1 2.3
2 1 1 1 1 2.3 0.7 1.2 2.1
1 1 2 2 2 2.1 1.1 1.2 2.6
2 1 2 2 2 1.4 1.2 1.4 2.8
1 1 2 2 2 0.8 0.9 1.2 2.4
1 2 2 2 2 0.7 1.2 1.4 2.1
1 2 2 2 2 1.1 1.2 1.2 2.4
1 1 2 2 2 3.1 1 1 2.1
1 1 2 2 2 2.1 1.1 1.1 2.4
2 1 2 2 2 1.1 0.8 1.1 2.2
1 1 2 2 2 1.4 0.6 1.3 2.6
1 1 2 2 2 0.8 0.6 1.5 2
1 1 2 2 2 0.6 0.8 1.2 2.4
2 2 2 2 2 1.4 0.7 1.1 2.8
1 2 2 2 2 1.3 0.8 1.4 2.6
1 2 2 2 2 1.1 1.1 1.3 2.9
1 2 2 2 2 1.6 1.2 1.2 2.2
1 1 2 2 2 0.9 1.2 1.1 2.3
2 1 2 2 2 1.4 1.1 1.3 1.8
2 1 2 2 2 1.2 0.7 1.1 2.3
2 1 2 2 2 2.3 0.7 1.2 2.1
1 1 2 2 2 2.1 1.1 1.2 2.6
1 1 2 2 2 2.1 1.1 1.3 2.2
1 1 2 2 2 1.2 0.7 1.2 2.6
1 2 2 2 2 1.1 0.9 1.4 2.1
2 1 2 2 2 2.3 1.1 1.4 1.9
1 1 1 2 2 1.1 0.6 1.2 2.1
1 1 2 2 2 0.7 0.8 1.2 2.1
2 1 2 2 2 1.2 0.8 1.3 2.2
2 1 2 2 2 1.1 0.9 1.1 1.9
2 1 2 2 2 1.2 1.1 1.2 2.1
2 1 2 2 2 2.1 1.2 1.1 1.9
2 2 2 2 2 1.3 0.8 1.2 2.1
2 1 2 2 2 0.8 0.7 1.1 2.4
2 1 2 2 2 1.4 1.1 1.3 1.8
2 1 2 2 2 1.2 0.7 1.1 2.3
1 1 2 2 2 2.3 0.7 1.2 2.1
2 1 2 2 2 2.1 1.1 1.2 2.6
2 1 2 2 2 1.4 1.2 1.4 2.8
2 1 1 1 2 0.8 0.9 1.2 2.4
2 1 2 2 2 0.7 1.2 1.4 2.1
2 1 2 2 2 1.1 1.2 1.2 2.4
2 1 1 1 2 3.1 1 1 2.1
2 1 2 2 2 2.1 1.1 1.1 2.4
1 1 2 2 2 1.1 0.8 1.1 2.2
2 1 2 2 2 1.4 0.6 1.3 2.6
2 2 2 2 2 0.8 0.6 1.5 2
1 1 2 2 2 1.3 0.8 1.4 2.6
1 1 2 2 2 1.1 1.1 1.3 2.9
2 1 2 2 2 1.6 1.2 1.2 2.2
2 1 2 2 2 0.9 1.2 1.1 2.3
2 1 2 2 2 2.1 1.1 1.1 2.4
2 1 2 2 2 1.4 0.6 1.3 2.6
2 1 2 2 2 1.1 0.8 1.1 2.2
2 2 2 2 2 1.3 0.8 1.2 2.1
2 2 2 2 2 0.8 0.7 1.1 2.4
2 2 2 2 2 1.4 1.1 1.3 1.8
2 2 2 2 2 1.2 0.7 1.1 2.3
2 2 2 2 2 2.3 0.7 1.2 2.1
2 2 2 2 2 2.1 1.1 1.2 2.6
2 2 2 2 2 1.4 1.2 1.4 2.8
1 2 2 2 2 0.8 0.9 1.2 2.4
2 2 1 1 2 0.7 1.2 1.4 2.1
1 2 2 2 2 3.1 1 1 2.1
2 2 2 2 2 1.1 1.2 1.2 2.4
2 2 1 2 2 0.8 0.8 1 2.2
1 1 2 2 2 1.2 0.8 1.1 2.1
2 1 2 2 2 1.3 1 1 2.4
1 1 2 2 2 1.4 0.90 1.1 2.3
2 2 1 2 2 1.2 1.1 1.2 2.1
2 1 2 2 2 1.3 0.9 1.1 2.1
2 2 2 2 2 1.1 0.8 0.8 2
2 1 2 2 2 1.1 1.2 1.9 2.3
1 1 2 2 2 1.2 1.1 1.3 2.6
2 2 2 2 2 1.2 0.9 1.1 2.3
2 2 1 2 2 1 1.2 1.3 2.3
2 2 2 2 2 1.1 1.1 1.2 1.9
2 2 1 2 2 1.4 1.3 1.2 1.9
2 2 1 1 2 1.7 0.8 1.2 2.4
1 2 1 2 2 1.3 1.2 1.1 2.1
1 1 1 1 2 1.6 1.2 1.2 2.1
1 1 2 2 2 1.1 1.1 1.3 2.3
2 2 1 1 2 1.7 0.9 1.2 2.2
2 1 1 2 2 1.2 1.2 1 2.1
1 2 1 1 2 1.2 0.9 1.1 2.4
2 2 1 1 2 1.2 0.9 1 1.8
2 1 1 1 2 1.1 1.1 1.2 2.5
2 2 1 1 2 1.2 1.1 1.1 2.2
1 1 1 1 2 11.1 1.36 1.3 2.3
1 1 1 1 2 7 0.9 1.5 2.4
1 1 2 1 1 2.3 0.8 1.3 2.4
2 1 2 2 2 1.8 0.7 1.1 2.6
1 1 2 2 2 1.2 1 1.6 2.4
1 1 1 1 2 1.5 1.2 1 2.1
1 2 1 1 2 1.4 1 1.3 2.5
1 1 2 2 2 1.1 1.6 1.2 2.4
1 2 2 2 2 1.1 1.2 1.1 2.2
1 1 2 2 2 2.4 0.5 1.2 1.9
1 2 2 2 2 1.3 1 1.3 1.8
2 1 2 2 2 1.2 1.1 1.1 1.9
2 1 1 1 2 1.2 1.3 1.2 2.4
1 2 1 1 1 2.1 0.7 1.7 2
2 1 2 2 2 1.5 0.6 1.2 2.5
2 1 1 1 1 1 1.1 1.2 2.1
2 2 1 1 2 8.4 0.4 1.6 1.8

CTP score at Baseline MELDscore at Baseline Bilirubin 3 months Creatinine 3 Months INR 3 months
7 9 1.2 1.2 1.1
7 10 1.3 1.4 0.9
8 10 1 1.3 1.1
7 8 1.2 1.6 1
8 11 1.2 0.8 1.3
8 13 1.1 0.9 1.1
8 9 1.2 1.1 1.2
8 11 2.1 1.2 1.1
8 14 1.3 0.8 1.2
7 9 0.8 0.7 1.1
7 8 1.4 1.1 1.3
8 10 1.2 0.7 1.1
8 8 2.3 0.7 1.2
7 10 2.1 1.1 1.2
8 12 1.4 1.2 1.4
7 9 0.8 0.9 1.2
7 7 0.7 1.2 1.4
8 12 1.1 1.2 1.2
7 8 3.1 1 1
7 12 2.1 1.1 1.1
7 12 1.1 0.8 1.1
8 13 1.4 0.6 1.3
7 8 1.4 1.2 1.4
7 12 0.8 0.9 1.2
7 11 0.7 1.2 1.4
8 11 1.1 1.2 1.2
8 11 3.1 1 1
7 8 2.1 1.1 1.1
7 11 1.1 0.8 1.1
7 11 1.4 0.6 1.3
7 8 0.8 0.6 1.5
7 9 0.6 0.8 1.2
8 11 1.4 0.7 1.1
8 11 1.3 0.8 1.4
8 12 1.1 1.1 1.3
7 9 1.6 1.2 1.2
7 12 0.7 0.8 1.2
8 13 1.2 0.8 1.3
8 9 1.1 0.9 1.1
8 11 1.2 1.1 1.2
8 14 2.1 1.2 1.1
7 9 1.3 0.8 1.2
7 8 0.8 0.7 1.1
8 10 1.4 1.1 1.3
8 8 1.2 0.7 1.1
7 10 2.3 0.7 1.2
8 12 2.1 1.1 1.2
7 9 1.4 1.2 1.4
7 7 0.8 0.9 1.2
8 12 0.7 1.2 1.4
7 8 1.1 1.2 1.2
7 12 3.1 1 1
7 12 2.1 1.1 1.1
8 13 1.1 0.8 1.1
7 8 1.4 0.6 1.3
7 12 0.8 0.6 1.5
7 11 0.7 1.2 1.4
8 11 1.1 1.2 1.2
8 11 3.1 1 1
7 8 2.1 1.1 1.1
7 11 1.1 0.8 1.1
7 11 1.4 0.6 1.3
7 9 0.8 0.6 1.5
7 7 0.7 1.2 1.4
8 12 1.1 1.2 1.2
7 8 3.1 1 1
7 12 2.1 1.1 1.1
7 12 1.1 0.8 1.1
8 13 1.4 0.6 1.3
8 9 0.8 0.6 1.5
8 11 0.6 0.8 1.2
8 11 1.4 0.7 1.1
7 8 1.3 0.8 1.4
7 11 1.1 1.1 1.3
7 11 1.6 1.2 1.2
7 12 0.9 1.2 1.1
7 11 2.1 1.1 1.1
8 11 1.1 0.8 1.1
8 11 1.2 0.7 1.2
7 8 1.1 0.9 1.4
7 11 2.3 1.1 1.4
7 11 1.1 0.6 1.2
7 8 0.7 0.8 1.2
8 11 1.1 0.9 1.1
7 9 1.2 0.8 1.3
8 8 2.1 1.2 1.1
7 10 1.3 0.8 1.2
8 12 0.8 0.7 1.1
7 9 1.4 1.1 1.3
7 7 1.2 0.7 1.1
8 12 2.3 0.7 1.2
7 8 2.1 1.1 1.2
7 12 1.4 1.2 1.4
7 12 0.8 0.9 1.2
8 13 0.7 1.2 1.4
7 8 1.1 1.2 1.2
7 12 3.1 1 1
7 11 2.1 1.1 1.1
8 11 1.1 0.8 1.1
8 11 1.4 0.6 1.3
7 8 1.4 1.2 1.4
7 11 0.8 0.9 1.2
7 11 0.7 1.2 1.4
7 8 1.1 1.2 1.2
7 9 3.1 1 1
8 11 2.1 1.1 1.1
8 11 1.1 0.8 1.1
8 12 1.4 0.6 1.3
7 9 0.8 0.6 1.5
8 12 0.6 0.8 1.2
7 8 1.4 0.7 1.1
7 12 1.3 0.8 1.4
7 12 1.1 1.1 1.3
8 13 0.8 0.7 1.1
8 9 1.4 1.1 1.3
8 11 1.2 0.7 1.1
8 14 2.3 0.7 1.2
7 9 2.1 1.1 1.2
7 8 2.1 1.1 1.3
8 10 1.2 0.7 1.2
8 8 1.1 0.9 1.4
7 10 2.3 1.1 1.4
8 12 1.1 0.6 1.2
7 9 0.7 0.8 1.2
7 7 1.2 0.8 1.3
8 12 1.1 0.9 1.1
7 8 1.2 1.1 1.2
7 12 2.1 1.2 1.1
7 12 1.3 0.8 1.2
8 13 0.8 0.7 1.1
7 8 1.4 1.1 1.3
7 12 1.2 0.7 1.1
7 11 2.3 0.7 1.2
8 11 2.1 1.1 1.2
8 11 1.4 1.2 1.4
7 8 0.8 0.9 1.2
7 11 0.7 1.2 1.4
7 11 1.1 1.2 1.2
8 11 3.1 1 1
8 11 2.1 1.1 1.1
8 12 1.1 0.8 1.1
7 9 1.4 0.6 1.3
8 11 2.1 1.1 1.1
7 11 1.4 0.6 1.3
7 8 1.1 0.8 1.1
7 9 1.4 1.1 1.3
7 7 1.2 0.7 1.1
8 12 2.3 0.7 1.2
7 8 2.1 1.1 1.2
7 12 1.4 1.2 1.4
7 12 0.8 0.9 1.2
8 13 0.7 1.2 1.4
7 8 1.1 1.2 1.2
7 12 3.1 1 1
8 11 1.1 0.8 1.1
7 11 2.1 1.1 1.1
8 6 3.6 1.2 1.2
7 8 1.2 0.7 1
7 7 1.2 0.80 1.2
7 9 3.4 1.2 1.1
8 10 1.4 1.1 1.2
7 8 1.4 1 1.2
7 7 1 0.9 1.2
9 16 2.4 1.2 1.7
8 11 1.2 1 1.6
7 8 1.2 1.1 1.1
7 11 1.6 1.4 1.6
8 10 1.2 1.6 1
8 12 0.8 1.2 1.4
7 11 1.2 2.1 1.2
8 10 1 0.9 1.4
8 12 2.1 1.2 1.9
8 11 1.2 1.1 1.8
8 10 1.3 1.9 1.2
9 9 6.2 0.4 1.7
7 8 1.2 1 1.2
7 7 1.6 1.4 1.6
7 10 11.2 0.6 1.4
7 9 1.4 1.3 1.4
7 21 9.2 0.8 1.8
7 18 1.7 0.8 2.6
7 13 19.2 5.6 1.7
7 10 20 3.6 2
7 12 20 3.4 1.3
7 10 1.5 1.2 1.8
7 11 45 1.1 1.9
7 13 2 0.9 1.4
8 10 1.5 0.6 1.2
8 12 8.2 0.7 1.3
8 10 1 2.3 1.1
9 9 7.8 1.4 1.2
8 12 1.1 1.4 1.6
10 15 6.8 1.4 1.6
7 7 6.36 0.8 1.1
9 9 8.7 1.8 1.5
8 20 23 2.6 1.9
Sex
Male 1
Female 2
Alcohol
Present 1
Absent 2
HBV infection
Present 1
Absent 2
Albumin 3 months CTP 3 Months MELD 3 month Bilirubin 6 months Creatinine 6 months
2.6 7 10 1.5 1.5
2.8 7 11 4.1 0.9
2.2 7 10 3.2 1.7
2.3 8 13 13.2 0.3
2.2 8 10 0.9 2.8
1.9 8 8 1.9 0.5
2.1 7 10 8.1 0.8
1.9 8 12 2 0.7
2.1 7 9 1.7 0.5
2.4 7 7 1.9 0.8
1.8 8 12 1.2 0.7
2.3 7 8 3.4 1.1
2.1 7 12 1.3 1.1
2.6 7 12 2.2 1
2.8 8 13 1 1
2.4 7 8 1 0.9
2.1 7 12 1 1.2
2.4 7 11 0.9 0.9
2.1 8 11 1.7 0.8
2.4 8 11 1.2 0.7
2.2 7 8 2.2 1
2.6 7 11 1 1
2.8 8 13 1 1
2.4 7 8 3.2 0.72
2.1 7 12 1.4 0.8
2.4 7 11 2.3 0.8
2.1 8 11 1.8 0.7
2.4 8 11 1.2 1
2.2 7 8 1.5 1.2
2.6 7 11 1.4 1
2 7 11 1.1 1.6
2.4 7 8 1.1 1.2
2.8 7 9 1.2 0.8
2.6 8 11 1.3 1.4
2.9 8 11 1.8 1.2
2.2 8 12 1 0.8
2.1 7 8 11.77 5.6
2.2 8 10 12.12 1.5
1.9 8 8 9.8 0.3
2.1 7 10 5.73 0.4
1.9 8 12 7.4 0.9
2.1 7 9 2.4 0.8
2.4 7 7 1.6 0.7
1.8 8 12 2.2 0.7
2.3 7 8 0.7 1.3
2.1 7 12 1.2 0.7
2.6 7 12 1.2 0.7
2.8 8 13 1.4 0.9
2.4 7 8 1.2 0.4
2.1 7 12 0.8 0.7
2.4 7 11 2.3 0.8
2.1 8 11 2 1.1
2.4 8 11 2.2 1.1
2.2 7 8 6.5 1.4
2.6 7 11 1.8 1
2 7 11 0.8 0.8
2.1 7 12 1.2 0.7
2.4 7 11 1.3 1
2.1 8 11 3.4 1.2
2.4 8 11 8.65 0.9
2.2 7 8 1.4 1
2.6 7 11 1 0.9
2 7 11 6 0.9
2.1 7 12 1.2 1
2.4 7 11 1.2 1.1
2.1 8 11 1 1.2
2.4 8 11 1.2 1.6
2.2 7 8 0.8 1.2
2.6 7 11 1.7 0.8
2 7 11 1 0.9
2.4 7 8 5.12 3.5
2.8 7 9 4 1.3
2.6 8 11 1.7 0.9
2.9 8 11 6.2 0.4
2.2 8 12 1.2 1
2.3 7 9 1.2 0.9
2.4 8 11 11.2 0.6
2.2 7 8 1.2 1.1
2.6 8 9 11.1 1.36
2.1 8 11 7 0.9
1.9 8 14 9.6 0.9
2.1 7 9 1.2 0.7
2.1 7 8 1.3 1
1.9 8 8 6.6 0.4
2.2 8 10 1.4 0.8
1.9 8 12 8.1 1.3
2.1 7 9 8.12 0.7
2.4 7 7 2.12 1.2
1.8 8 12 1 1.4
2.3 7 8 2 0.8
2.1 7 12 0.7 1.1
2.6 7 12 1.6 1.5
2.8 8 13 0.8 1.5
2.4 7 8 2 1.1
2.1 7 12 0.5 0.8
2.4 7 11 1.7 1
2.1 8 11 1.7 0.8
2.4 8 11 1 0.7
2.2 7 8 1.7 1.1
2.6 7 11 1.2 0.7
2.8 8 13 1 0.7
2.4 7 8 1 0.9
2.1 7 12 1.4 1
2.4 7 11 0.8 0.9
2.1 8 11 1.2 0.9
2.4 8 11 1.2 1.1
2.2 7 8 1.2 1
2.6 7 11 0.7 0.9
2 7 11 0.7 0.9
2.4 7 8 1.4 0.8
2.8 7 9 2.3 0.8
2.6 8 11 1.8 0.7
2.9 8 11 1.2 1
2.4 7 7 1.5 1.2
1.8 8 12 1.4 1
2.3 7 8 1.1 1.6
2.1 7 12 1.1 1.2
2.6 7 12 2.4 0.5
2.2 8 13 1.3 1
2.6 8 9 1.2 1.1
2.1 8 11 1.1 1.4
1.9 8 14 2.1 0.7
2.1 7 9 6.36 0.8
2.1 7 8 1 1.1
2.2 8 10 8.4 0.4
1.9 8 8 14.1 0.8
2.1 7 10 1.6 0.9
1.9 8 12 2.7 1.1
2.1 7 9 1.1 0.9
2.4 7 7 3.8 0.9
1.8 8 12 3.3 2.7
2.3 7 8 1.3 1
2.1 7 12 8.1 1
2.6 7 12 7.7 1.6
2.8 8 13 0.7 1.2
2.4 7 8 1 1.1
2.1 7 12 6.3 1.4
2.4 7 11 6.6 0.8
2.1 8 11 4 0.5
2.4 8 11 0.7 1
2.2 7 8 0.6 0.90
2.6 7 11 0.6 0.6
2.4 8 11 0.9 0.8
2.6 7 11 16.1 0.9
2.2 7 8 2.6 0.6
1.8 8 12 3.2 0.8
2.3 7 8 1.9 1
2.1 7 12 1 1.1
2.6 7 12 0.6 0.8
2.8 8 13 1.6 0.7
2.4 7 8 6.21 1.8
2.1 7 12 2 1
2.4 7 11 1.2 1.1
2.1 8 11 6.21 1.8
2.2 7 8 1 0.5
2.4 8 11 1.9 1
2.5 9 15 7.7 1.2
2.3 8 13 1.4 0.8
2.3 8 9 12.17 0.80
2.1 9 14 6 0.90
2.1 9 11 8.65 0.9
2.3 8 10 9.4 0.9
2.3 8 8 1.2 0.8
2.3 8 17 6 0.9
2.1 8 12 2.5 1.1
2 8 9 2.8 0.9
2.5 9 17 3.4 1.4
2.4 7 12 4.5 1.1
2.6 7 12 1.4 1.3
2 9 16 1.2 2.1
2.1 7 10 4.1 1.2
2.1 9 18 5.12 3.5
2.3 8 15 4 1.3
2.3 9 16 2.1 1.9
2.3 7 19 2.4 1.2
2.4 7 9 4 2.2
2.2 10 17 20 4.5
2.2 7 19 5.12 3.5
2.1 9 14 2.6 1.8
1.9 9 21 - -
1.8 10 19 - -
1.9 11 37 - -
2.1 12 38 - -
2.4 12 32 - -
2.3 9 16 - -
2.8 9 29 - -
2.7 9 13 - -
2.5 8 10 - -
2.4 9 17 - -
2.2 9 15 - -
2.7 9 19 - -
1.9 11 15 - -
1.9 8 22 - -
2.1 10 15 - -
2.3 11 25 - -
2.1 12 35 - -
Others variceal Bleed
Present 1 Present 
Absent 2 Absent
Status on waiting list HRS
Alive 1 Present 
Died 2 Absent
HCV infection
Present 1
Absent 2
INR 6 months Albumin 6 month CTP 6 month ELD 6 mon Status
2.2 1.9 12 21 1
1.9 1.8 12 19 1
1.2 1.9 9 18 1
1.9 1.9 11 24 1
1.1 2 10 17 1
1.7 2.1 9 15 1
1.1 2.1 9 15 1
1.6 2.3 8 14 1
1.7 2.3 8 14 1
1.4 2.1 8 13 1
1 2.1 8 13 1
1 2 8 12 1
1.4 2 8 12 1
1.2 2.2 8 12 1
1.2 2.3 7 11 1
1.5 2.4 7 11 1
1.3 2.3 7 11 1
1.4 2.6 7 10 1
1 2.4 7 8 1
0.9 2.4 7 7 1
1.2 2.2 8 12 1
1.2 2.3 7 11 1
1.2 2.4 8 11 1
1.4 1.9 10 15 1
1.2 2.3 7 10 1
1.3 2.6 7 13 1
1.1 2.6 7 10 1
1.6 2.4 7 12 1
1 2.1 7 10 1
1.3 2.5 7 11 1
1.2 2.4 7 13 1
1.1 2.2 8 10 1
1.4 2.3 7 11 1
1.3 2.4 7 14 1
1.4 1.8 9 14 1
1.2 2.2 7 8 1
2.9 1.8 12 41 1
1.3 1.9 9 23 1
1.7 1.9 11 21 1
1.2 2 10 16 1
1.1 2.1 9 15 1
1.2 2.1 9 12 1
1.4 2.3 8 12 1
1.2 2.3 8 11 1
1.2 2.1 8 11 1
1.3 2.1 8 10 1
1.2 2 8 10 1
1.2 2 8 10 1
1.3 2.2 8 10 1
1 2.3 7 6 1
1.1 2.4 7 11 1
2 2.3 9 27 1
2.1 2.6 7 19 1
1.7 2.4 7 23 1
1.2 2.4 7 11 1
1 2.2 8 6 1
1 2.3 7 13 1
1 2.4 7 7 1
1.1 2.1 9 14 1
1.8 2.1 9 21 1
1.2 2.3 8 10 1
1.2 2.3 8 8 1
1.7 2.1 9 19 1
1.6 2.1 8 12 1
1.1 2 8 9 1
1.3 2.3 7 11 1
1 2.4 7 12 1
1.4 2.6 7 12 1
1.2 2.4 7 11 1
1.4 2.1 7 10 1
1.2 2.5 8 27 1
1.7 2.4 7 20 1
1.2 2.2 8 10 1
1.7 2.3 7 19 1
1.2 2.4 7 9 1
1 1.8 7 7 1
1.4 2.2 7 19 1
1.1 2.2 7 9 1
1.3 2.3 7 21 1
1.5 2.4 7 18 1
1.5 2.1 9 20 1
1 2.1 7 7 1
1.3 2.3 8 10 1
1 2.1 8 13 1
1.1 2.3 8 9 1
1.4 1.8 9 21 1
1.5 2.1 9 19 1
1.3 2.1 8 14 1
1.5 2.5 7 14 1
1.5 2.4 7 14 1
1.1 2.2 7 8 1
1.1 2.3 8 13 1
1.3 2.4 7 13 1
1.1 2.1 8 11 1
1 2.2 7 6 1
1.1 2.3 7 10 1
1.2 2.4 7 10 1
1.4 2.6 7 10 1
1 2.4 7 9 1
1.2 2.1 7 9 1
1.2 2.5 7 8 1
1.1 2.4 7 7 1
1.1 2.2 8 9 1
1.2 2.3 7 8 1
1 2.4 7 7 1
1.1 1.8 9 9 1
1 2.2 7 7 1
1 2.2 8 6 1
1 2.3 7 6 1
1.2 2.3 7 10 1
1.3 2.4 7 13 1
1.1 2.6 7 10 1
1.6 2.4 7 12 1
1 2.1 7 10 1
1.3 2.5 7 11 1
1.2 2.4 7 13 1
1.1 2.2 8 10 1
1.2 1.9 12 12 1
1.3 1.8 12 10 1
1.1 1.9 9 9 1
1.6 1.9 11 15 1
1.7 2 10 15 1
1.1 2.1 9 15 1
1.2 2.1 9 9 1
1.6 1.8 8 20 1
1.2 2.3 8 18 1
1.1 2.1 8 9 1
1 2.1 8 11 1
1.9 2 8 12 1
1 2 8 11 1
1.1 2.2 8 22 1
1.3 2.3 7 10 1
1.5 2.4 7 19 1
1.3 2.3 7 22 1
1.1 2.6 7 9 1
1 2.4 7 6 1
3.1 2.1 9 29 1
1.6 2.2 8 19 1
1.8 2.3 7 18 1
1.3 2.4 7 9 1
1.2 2.4 7 8 1
1.1 2.3 8 7 1
1.5 2.1 8 11 1
1.2 1.9 10 19 1
1.2 2.4 7 12 1
1.4 2.1 7 15 1
1.4 2.4 7 14 1
1.6 2.1 8 13 1
1.2 2.4 8 9 1
1.1 2.2 7 14 1
1.5 2.1 8 23 1
1 2 7 9 1
1 2.4 7 8 1
1.5 2.1 8 23 1
1.2 2.9 7 8 1
1.4 2.6 8 14 1
1.7 2.5 10 22 2
1.1 2.1 7 9 2
1.8 2.3 11 22 2
1.7 2.3 10 19 2
1.8 2.1 9 21 2
2 2.1 10 23 2
1.4 2 8 11 2
1.7 2.1 9 19 2
1.8 2.6 8 17 2
1.5 2.3 8 15 2
1.7 2.5 10 20 2
1.8 1.9 9 20 2
1.4 1.9 9 14 2
1.7 2 10 20 2
1.9 2.1 10 21 2
1.2 2.5 8 27 2
1.7 2.4 7 20 2
1.5 2.3 10 20 2
2.1 2.1 9 20 2
1.7 2.4 11 25 2
1.9 2.2 12 38 2
1.2 2.5 11 27 2
2 2.1 12 23 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
- - - - 2
SBP
1 Present 1
2 Absent 2
Hepatic encephalopathy
1 Present 1
2 Absent 2
                                              ABBREVIATIONS 
 
CTP                 : Child Turcotte Pugh Score 
MELD             : Model for End Stage Liver Disease. 
PELD              : Pediatric End Stage Liver Disease.   
INR                 : International Normalized Ratio  
ICG                  : Indocyanine Green 
UNOS             :  United Network for Organ Sharing  
HBV               :  Hepatitis B Virus  
HCV               : Hepatitis C Virus 
HIV               : Human Immunodeficiency Virus 
ROC              : Receiver operating characteristic  
PT                  : Prothrombin time  
HE                  : Hepatic encephalopathy. 
HRS               : Hepato renal syndrome. 
SBP                : Spontaneous Bacterial Peritonitis. 
MEGX           : Monoethylglycinexylidide  
TNM              : Tumor Node Metastasis 
APACHE       : Acute Physiology and Chronic Health and Evaluation 
HCC              : Hepatocellular carcinoma. 
TIPS              : Transjugular Intrahepatic Portosystemic Shunt. 
 
 
 
 
PROFORMA 
 
Name                                                 Age/Sex: …../….. MGE no: /….DOR …/…/… 
 
Address                                              Occupation …………….  Income ……….        
 
 BLOOD GROUP:                             Contact number 
 
DIAGNOSIS: 
                                   ……………………………………………………………….. 
Chief complaints 
 
      Distension of Abdomen 
 
      Pedal Edema 
 
 HPI                                                      Duration… 
      
Distension of Abdomen 
 
Abdominal pain (RUQ) 
 
Pedal edema 
 
Fever 
 
Jaundice 
 
Loss of weight 
 
Loss of appetite 
 
Bleeding PR 
 
PAST H/O          DM/HT/TB/Abdominal surgery/others 
 
Family h/o          Cancer 
 
Personal h/o      Alcohol/Smoking/Tobacco 
 
O/E 
                   Signs of weight loss             ………………………………… 
                   Abdominal / pelvic mass       ……………………………….. 
                   Percussion for fluid.              ………………………………… 
                   Groin or neck nodes              …………………………………… 
                    PR mass/blood                    ………………………………… 
 
 Investigations 
 
 CBC                                                              L F T 
     Hb%                                                                S. Bilirubin T …..  /D …… 
     TC                                                                   SGOT /SGPT ……../………            
     DC                                                                   TOTAL Protein ……. / Alb…. 
     ESR                                                                  SAP              ……………… 
     Platelets 
     Prothrombin time: …… 
     INR: 
      
Blood                                                             Ascitic fluid analysis 
      Urea                                                             Cell count   
       Sugar                                                          Albumin 
       Creatinine                                                   Gram stain                                                       
       Electrolytes                                                 Culture 
 
S. Amylase    ……..                                            Amylase 
S. Lipase        …….. .                                          Cytology 
AFP               ………                                           Mycobacterial culture 
 
 
CXR     :                                                      VIRAL MARKERS 
AXR     :                                                           HBsAg      : 
USG Abdomen:                                                Anti HCV: 
 
             
PV Doppler: 
 
CTSCAN: 
 
 
ENDOSCOPY: 
 
 
 Base line  At 3 months At 6months 
Sr.Bilirubin.    
Sr. Creatinine.    
INR    
Albumin    
CTP    
MELD    
 
